The inflamed SCLC subtype (SCLC-I) exhibits a mesenchymal and inflammatory phenotype with increased expression of human leukocyte antigens (HLAs), interferon-γ (IFN-γ) activation, and immune checkpoints, consistent with the association between EMT- and immune-related gene expressions [64]. The gene discussed is HLA-S; the disease is small cell lung carcinoma.